MAP2 and neoplasm: The peptide Lt-MAP2 showed the highest activity (Emax) in C1498 and K562 lines, respectively, which also corresponded to the highest observed potency (EC50), however, when compared with the commercial antineoplastic drug, daunorubicin, was observed more efficient than the peptides, promoting a reduction the tumor cell viability at concentrations 50 and 25 μg.ml−1 for C1498 and K562, respectively (Supplementary Table 2).